메뉴 건너뛰기




Volumn 36, Issue 2, 2016, Pages 189-197

Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients

(20)  Everson, Gregory T a   Sims, Karen D b   Thuluvath, Paul J c   Lawitz, Eric d   Hassanein, Tarek e   Rodriguez Torres, Maribel f   Desta, Tadesse g   Hawkins, Trevor h   Levin, James M i   Hinestrosa, Federico j   Rustgi, Vinod k   Schwartz, Howard l   Younossi, Zobair m   Webster, Lynn n   Gitlin, Norman o   Eley, Timothy b   Huang, Shu Pang b   Mcphee, Fiona b   Grasela, Dennis M b   Gardiner, David F b  


Author keywords

Direct acting antiviral; Drug combination; Liver disease; Therapy

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR; BECLABUVIR; BILIRUBIN; DACLATASVIR; GLUCOSE; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PHOSPHATE; RIBAVIRIN; VIRUS RNA; 8-CYCLOHEXYL-N-((DIMETHYLAMINO)SULFONYL)-1,1A,2,12B-TETRAHYDRO-11-METHOXY-1A-((3-METHYL-3,8-DIAZABICYCLO(3.2.1)OCT-8-YL)CARBONYL)CYCLOPROP(D)INDOLO(2,1-A)(2)BENZAZEPINE-5-CARBOXAMIDE; ANTIVIRUS AGENT; BENZAZEPINE DERIVATIVE; BMS-790052; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; SULFONAMIDE;

EID: 84955481913     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12964     Document Type: Article
Times cited : (26)

References (28)
  • 1
    • 84955465082 scopus 로고    scopus 로고
    • Hepatitis C key facts. WHO factsheet No 164. July 2013. 2013.
    • World Health Organization. Hepatitis C key facts. WHO factsheet No 164. July 2013. 2013.
  • 2
    • 84867308646 scopus 로고    scopus 로고
    • Global burden of hepatitis C: considerations for healthcare providers in the United States
    • Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis 2012; 55(Suppl. 1): S10-5.
    • (2012) Clin Infect Dis , vol.55 , pp. S10-S15
    • Averhoff, F.M.1    Glass, N.2    Holtzman, D.3
  • 3
    • 84872026806 scopus 로고    scopus 로고
    • Current management and perspectives for HCV recurrence after liver transplantation
    • Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013; 33(Suppl. 1): 56-62.
    • (2013) Liver Int , vol.33 , pp. 56-62
    • Coilly, A.1    Roche, B.2    Samuel, D.3
  • 4
    • 84882907540 scopus 로고    scopus 로고
    • Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C
    • Accessed 27 November 2015.
    • American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available at http://www.hcvguidelines.org/fullreport/hcv-testing-and-linkage-care. Accessed 27 November 2015.
  • 5
    • 84931560807 scopus 로고    scopus 로고
    • EASL Recommendations on Treatment of Hepatitis C 2015
    • European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 2015; 63: 199-236.
    • (2015) J Hepatol , vol.63 , pp. 199-236
  • 6
    • 79959438789 scopus 로고    scopus 로고
    • Telaprevir for previously untreated chronic hepatitis C virus infection
    • Jacobson IM, McHutchison JG, Dusheiko G, etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
    • (2011) N Engl J Med , vol.364 , pp. 2405-2416
    • Jacobson, I.M.1    McHutchison, J.G.2    Dusheiko, G.3
  • 7
    • 79953173221 scopus 로고    scopus 로고
    • Boceprevir for untreated chronic HCV genotype 1 infection
    • Poordad F, McCone J Jr, Bacon BR, etal. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
    • (2011) N Engl J Med , vol.364 , pp. 1195-1206
    • Poordad, F.1    McCone, J.2    Bacon, B.R.3
  • 8
    • 84906053496 scopus 로고    scopus 로고
    • Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
    • Jacobson IM, Dore GJ, Foster GR, etal. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-13.
    • (2014) Lancet , vol.384 , pp. 403-413
    • Jacobson, I.M.1    Dore, G.J.2    Foster, G.R.3
  • 9
    • 84877730954 scopus 로고    scopus 로고
    • Sofosbuvir for previously untreated chronic hepatitis C infection
    • Lawitz E, Mangia A, Wyles D, etal. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
    • (2013) N Engl J Med , vol.368 , pp. 1878-1887
    • Lawitz, E.1    Mangia, A.2    Wyles, D.3
  • 10
    • 77952035218 scopus 로고    scopus 로고
    • Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
    • Gao M, Nettles RE, Belema M, etal. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
    • (2010) Nature , vol.465 , pp. 96-100
    • Gao, M.1    Nettles, R.E.2    Belema, M.3
  • 11
    • 84866334428 scopus 로고    scopus 로고
    • Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032)
    • McPhee F, Sheaffer AK, Friborg J, etal. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother 2012; 56: 5387-96.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 5387-5396
    • McPhee, F.1    Sheaffer, A.K.2    Friborg, J.3
  • 12
    • 84969429096 scopus 로고    scopus 로고
    • Discovery of BMS-791325, an allosteric NS5B replicase inhibitor for the treatment of hepatitis C virus [abstract]
    • Kadow J, Gentles RG, Ding M, etal. Discovery of BMS-791325, an allosteric NS5B replicase inhibitor for the treatment of hepatitis C virus [abstract]. 243rd ACS National Meeting and Exposition 2012: Abstract MEDI-23.
    • 243rd ACS National Meeting and Exposition 2012
    • Kadow, J.1    Gentles, R.G.2    Ding, M.3
  • 13
    • 84892761609 scopus 로고    scopus 로고
    • Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection
    • Everson GT, Sims KD, Rodriguez-Torres M, etal. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology 2014; 146: 420-9.
    • (2014) Gastroenterology , vol.146 , pp. 420-429
    • Everson, G.T.1    Sims, K.D.2    Rodriguez-Torres, M.3
  • 14
    • 82455188181 scopus 로고    scopus 로고
    • Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
    • Nettles RE, Gao M, Bifano M, etal. Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011; 54: 1956-65.
    • (2011) Hepatology , vol.54 , pp. 1956-1965
    • Nettles, R.E.1    Gao, M.2    Bifano, M.3
  • 15
    • 84862560600 scopus 로고    scopus 로고
    • Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir
    • McPhee F, Friborg J, Levine S, etal. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother 2012; 56: 3670-81.
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 3670-3681
    • McPhee, F.1    Friborg, J.2    Levine, S.3
  • 16
    • 82455192239 scopus 로고    scopus 로고
    • Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: invitro and invivo correlations
    • Fridell RA, Wang C, Sun JH, etal. Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: invitro and invivo correlations. Hepatology 2011; 54: 1924-35.
    • (2011) Hepatology , vol.54 , pp. 1924-1935
    • Fridell, R.A.1    Wang, C.2    Sun, J.H.3
  • 17
    • 84873054024 scopus 로고    scopus 로고
    • Characterization of viral escape in HCV genotype 1-infected patients treated with BMS-791325 and pegylated interferon-alfa and ribavirin
    • McPhee F, Falk P, Lemm J, etal. Characterization of viral escape in HCV genotype 1-infected patients treated with BMS-791325 and pegylated interferon-alfa and ribavirin. J Hepatol 2012; 56(Suppl. 2): S473.
    • (2012) J Hepatol , vol.56 , pp. S473
    • McPhee, F.1    Falk, P.2    Lemm, J.3
  • 18
    • 84856159009 scopus 로고    scopus 로고
    • Preliminary study of two antiviral agents for hepatitis C genotype 1
    • Lok AS, Gardiner DF, Lawitz E, etal. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366: 216-24.
    • (2012) N Engl J Med , vol.366 , pp. 216-224
    • Lok, A.S.1    Gardiner, D.F.2    Lawitz, E.3
  • 19
    • 84894099866 scopus 로고    scopus 로고
    • Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
    • Lok AS, Gardiner DF, Hezode C, etal. Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders. J Hepatol 2014; 60: 490-9.
    • (2014) J Hepatol , vol.60 , pp. 490-499
    • Lok, A.S.1    Gardiner, D.F.2    Hezode, C.3
  • 20
    • 84879693219 scopus 로고    scopus 로고
    • Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
    • Suzuki Y, Ikeda K, Suzuki F, etal. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58: 655-62.
    • (2013) J Hepatol , vol.58 , pp. 655-662
    • Suzuki, Y.1    Ikeda, K.2    Suzuki, F.3
  • 21
    • 84857395452 scopus 로고    scopus 로고
    • Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
    • Chayama K, Takahashi S, Toyota J, etal. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742-8.
    • (2012) Hepatology , vol.55 , pp. 742-748
    • Chayama, K.1    Takahashi, S.2    Toyota, J.3
  • 22
    • 84892619580 scopus 로고    scopus 로고
    • Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
    • Sulkowski MS, Gardiner DF, Rodriguez-Torres M, etal. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21.
    • (2014) N Engl J Med , vol.370 , pp. 211-221
    • Sulkowski, M.S.1    Gardiner, D.F.2    Rodriguez-Torres, M.3
  • 23
    • 78649251945 scopus 로고    scopus 로고
    • A perspective on modelling hepatitis C virus infection
    • Guedj J, Rong L, Dahari H, Perelson AS. A perspective on modelling hepatitis C virus infection. J Viral Hepat 2010; 17: 825-33.
    • (2010) J Viral Hepat , vol.17 , pp. 825-833
    • Guedj, J.1    Rong, L.2    Dahari, H.3    Perelson, A.S.4
  • 24
    • 84955473708 scopus 로고    scopus 로고
    • ™ (Simeprevir) Prescribing Information. 2014.
    • ™ (Simeprevir) Prescribing Information. 2014.
  • 25
    • 84900339263 scopus 로고    scopus 로고
    • Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection
    • Afdhal N, Zeuzem S, Kwo P, etal. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
    • (2014) N Engl J Med , vol.370 , pp. 1889-1898
    • Afdhal, N.1    Zeuzem, S.2    Kwo, P.3
  • 26
    • 84901044326 scopus 로고    scopus 로고
    • ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
    • Ferenci P, Bernstein D, Lalezari J, etal. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. NEngl J Med 2014; 370: 1983-92.
    • (2014) NEngl J Med , vol.370 , pp. 1983-1992
    • Ferenci, P.1    Bernstein, D.2    Lalezari, J.3
  • 27
    • 84929207643 scopus 로고    scopus 로고
    • Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
    • Poordad F, Sievert W, Mollison L, etal. Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. JAMA 2015; 313: 1728-35.
    • (2015) JAMA , vol.313 , pp. 1728-1735
    • Poordad, F.1    Sievert, W.2    Mollison, L.3
  • 28
    • 84929208843 scopus 로고    scopus 로고
    • Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C genotype 1 infection with compensated cirrhosis
    • Muir A, Poordad F, Lalezari JP, etal. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C genotype 1 infection with compensated cirrhosis. JAMA 2015; 313: 1736-44.
    • (2015) JAMA , vol.313 , pp. 1736-1744
    • Muir, A.1    Poordad, F.2    Lalezari, J.P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.